$70.96
2.94% yesterday
Nasdaq, Apr 03, 10:00 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$70.96
+1.63 2.35% 1M
-72.84 50.65% 6M
+8.61 13.81% YTD
-4.39 5.83% 1Y
+43.37 157.19% 3Y
+59.08 497.31% 5Y
+54.96 343.50% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-2.15 2.94%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Market capitalization $2.39b
Enterprise Value $2.57b
P/E (TTM) P/E ratio 70.24
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.82
P/S ratio (TTM) P/S ratio 5.41
P/B ratio (TTM) P/B ratio 10.44
Revenue growth (TTM) Revenue growth 82.74%
Revenue (TTM) Revenue $441.54m
EBIT (operating result TTM) EBIT $37.50m
Free Cash Flow (TTM) Free Cash Flow $-80.94m
Cash position $336.65m
EPS (TTM) EPS $1.01
P/E forward 50.95
P/S forward 4.40
EV/Sales forward 4.74
Short interest 34.49%
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
70%
Hold
30%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
442 442
83% 83%
100%
- Direct Costs 180 180
105% 105%
41%
262 262
70% 70%
59%
- Selling and Administrative Expenses 148 148
34% 34%
34%
- Research and Development Expense 56 56
55% 55%
13%
57 57
698% 698%
13%
- Depreciation and Amortization 20 20
128% 128%
4%
EBIT (Operating Income) EBIT 37 37
2,575% 2,575%
8%
Net Profit 35 35
242% 242%
8%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Neutral
PRNewsWire
about 14 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in TransMedics between February 23, 2023 and January 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 87...
Neutral
Accesswire
about 17 hours ago
Investors Who Acquired TransMedics Securities Between February 28, 2023 and January 10, 2025 (the "Class Period") May Have Legal Claims. PHILADELPHIA, PA / ACCESS Newswire / April 3, 2025 / Kehoe Law Firm, P.C.
Neutral
GlobeNewsWire
about 17 hours ago
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) securities between February 28, 2023 and Januar...
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 728
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today